Summary
President Donald Trump announced agreements to reduce the costs of popular weight-loss drugs. The deals involve Eli Lilly and Novo Nordisk and aim to make medications more affordable through government healthcare plans like Medicare and Medicaid. These actions are part of the administration's focus on lowering pharmaceutical prices.
Key Facts
- President Trump unveiled agreements to lower costs for weight-loss drugs made by Eli Lilly and Novo Nordisk.
- The drugs include Wegovy and Zepbound, and consumers will pay between $245 and $350 per month.
- Without insurance or discounts, these GLP-1 drugs can cost over $1,000 per month.
- The deals will expand access through Medicare and Medicaid, making some drugs available for $50 a month for eligible users.
- Eli Lilly will be exempt from tariffs for three years as part of the agreement.
- TrumpRx, a new government-run website, will offer these drugs at discounted prices starting in January.
- Federal law currently restricts Medicare from covering weight-loss drugs unless they treat other conditions like diabetes.
- Trump has been urging pharmaceutical companies to lower drug prices and has secured deals with Pfizer and others as part of this effort.
